{
  "pmcid": "9311282",
  "sha256": "30f42546c5ace033c5af1cd16da63d84afd2c70ec8971ffa4fb8adde8392cf07",
  "timestamp_utc": "2025-11-10T00:12:15.315192+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.004383993692098,
    "reading_ease": 26.856972205795415,
    "word_count": 267
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Immunosuppressive Regimens on COVID-19 Vaccine Response in Elderly Kidney Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "The OPTIMIZE trial, an open-label, randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "enrolled elderly KTRs (â‰¥65 years) at the University Medical Center Groningen"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to either a standard regimen of calcineurin inhibitor (CNI), mycophenolate mofetil (MMF), and prednisolone, or a regimen with low-dose CNI, everolimus, and prednisolone"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the impact of different immunosuppressive regimens on vaccine efficacy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was seroconversion rate, assessed after 2 and 3 COVID-19 mRNA vaccinations."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Participants were randomised"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Randomisation was open-label, and outcome assessors were not blinded."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "A total of 32 participants were analysed for humoral response, and 15 for cellular response."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "seroconversion rates were 13% after 2 vaccinations and 38% after 3 vaccinations. In contrast, the everolimus group showed significantly higher rates of 56% (p = 0.009) and 100% (p = 0.006), respectively."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported during the study."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrials.gov Identifier: NCT03797196"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}